I gave a talk at at the IQPC Predictive Toxicology Conference in London, UK on 24 February. In this presentation I discuss the critical role of interoperability in collaboration situations in drug design and predictive toxicology. I reflect on the inspiration of the Tamboti Tree Use Case from our recent conservation work trip to South Africa. The role of intereroperability and ontology development in the OpenTox predictive toxicology framework is discussed. The evolution of development and prototyping within OpenTox has demonstrated its potential as a Semantic Web for Predictive Toxicology, alternative testing methods and risk assessment. Several recent OpenTox interoperations have been achieved including with Bioclipse, CDK, ToxCast, and Leadscope. OpenTox will provide a valuable open standards based foundation on which to create services and link resources for the new ToxBank infrastructure project.
I provide an overview of the approach used in the FP7 Synergy project where we have established a Scientists Against Malaria virtual organisation which is carrying out a number of modelling and experimental drug design activities against a kinase target in Plasmodium, the parasite that causes malaria. We use an ontological approach to interoperate between a collaborative electronic notebook, Synergy collaboration services and event-driven recommendation rules for consensus formation and traffic light discussion and decision making on conflicting predictions or experimental results.
I will deliver an OpenTox seminar at the IQPC (Pharma IQ) Predictive Toxicology conference taking place in London 23-24 Feb 2011, in which I will present on recent developments with regards to OpenTox interoperability advances, and particularly to support of collaborative drug discovery projects. Also of interest to the increasing support by OpenTox of in vitro methods is a significant program on stem cell technology. The conference will address the accuracy of drug safety testing through the integration of advanced prediction methods, including stem cell based assays and screening into safety evaluation strategies. The main conference will take place in London on 23rd-24th February 2011 and new for this year, there will be a pre-conference focus day on 22nd February 2011 dedicated to the use of stem cells as a tool to enhance predictive toxicology. http://www.predictivetoxicology.co.uk/Event.aspx?id=394530
During April - October 2010 we will be running two pilots which will create two virtual organisations (VOs) of research partners who will collaborate on a drug discovery and a predictive toxicology project.
We are currently seeking Expressions of Interest in the ICT support role for the pilots which should be submitted by 17.00 CET, 19 February 2010 through the following form: https://www.surveymonkey.com/s/QSHKDCH
The VOs will be created from partners from Douglas Connect Collaboration Pools, who will bring contributing knowledge, computational or experimental capabilities to the partnership for the duration of the projects:
a) Drug Design project will examine the application of a variety of leading modelling and design approaches to novel target kinases, to experimentally test predictions, and to initiate a best practices virtual screening resource.
b) Predictive Toxicology project will apply a combination of in silico and in vitro approaches to predict in vivo toxicity including exposure.
The ICT support role will support the informatics requirements of the researchers in organising, processing and sharing data, and in collaborative analysis and decision making.
The VOs will be supported by knowledge-oriented collaboration services developed under the FP7 Synergy research project, including a reactive complex event driven engine, collaboration moderator, collaboration pattern services and partner knowledge base. Summary on Synergy project: http://barryhardy.blogs.com/theferryman/2008/02/knowledge-orien.html
The Predictive Toxicology VO will be supported by distributed REST-driven web services for data management, model building, validation and reporting, developed under the OpenTox Framework (http://www.opentox.org/)
Barry Hardy PhD Director, Community of Practice & Research Activities and OpenTox Project Coordinator (www.opentox.org) Douglas Connect Switzerland
When I started the eCheminfo community of practice in late 2003 we focused initially on using the approach of virtual conferencing and communications to get the community started. More recently I have given more attention to developing face-to-face conference and workshop activity and initiating collaborative research. While on this journey it has been personally rewarding to have met and made contact with hundreds of scientists in the international community and to additionally be involved in supporting their networking, career development and research in drug design, discovery and modelling. It has also been rewarding to have just met so many great people and to have had the chance to interact with them, be it on a computer, in a workshop exercise, or on a punt trying to get down the river as we usually do when we are in Oxford. So far we seem to be better on computer-based physics than boat physics!
And so I have come full circle and can see the need to prioritise the virtual community aspects of eCheminfo further again, to support the continuation of all these worthwhile interactions in the community. So LinkedIn is one place to start. I have been on there for some years and we have had a group area, but have not really done much with it. It has primarily been useful for some introductions between people. However recent feature additions for discussion, posting of news, job announcements etc. have been added, so it seems worthwhile to try using it more for supporting continuing interactions in the community. So I am initiating today invitations to the eCheminfo community to join us there for discussion, news and networking on what is happening in the world of drug discovery informatics, cheminformatics, bioinformatics, etc. Use of the group is intended for scientific and professional exchange purposes only. As included in our mission we encourage cross-disciplinary cross-sector participation so from medicinal chemists in the pharmaceutical industry through toxicologists in government institutes through PhD students working on their modelling research problems are welcome!
To request joining the eCheminfo LinkedIn group please follow the following link and introduce yourself with a group joining request:
The eCheminfo Autumn Community of Practice meeting will take place the week of October 15 at Bryn Mawr College, Philadelphia to discuss latest research applications, methods and best practices in drug discovery informatics, design and modelling.
The following conference sessions will be held:
16 October: Virtual Screening, chaired by Christopher Austin (NIH) and Ajay Jain (UCSF)
16 October: Structural Biology, chaired by Max Cummings (Tibotec Pharmaceuticals)
17 October: Structure-based Drug Design, chaired by Jose Duca (Schering-Plough)
17 October: Fragment-based Drug Discovery, chaired by Maria Kontoyianni (Crystax Pharmaceuticals)
18-19 October: Predictive ADME/Toxicology, chaired by Tony Hopfinger (University of New Mexico College of Pharmacy)
Additional workshop activity on virtual screening best practices, knowledge management in R&D and advances in predictive ADME and toxicology will also be held.
Conference speakers include:
Stephen Burley (SGX Pharmaceuticals), Georgia McGaughey (Merck), Charles Lesburg (Schering-Plough), Rick Beger (FDA), Marc Nicklaus (NIH), Woody Sherman (Schrodinger), Daniel Cheney (Bristol Myers Squibb), Paul Labute (Chemical Computing Group), Ajay Jain (UCSF), Alan Cheng (Amgen), Tony Hopfinger (University of New Mexico), Anthony Klon (Pharmacopeia Drug Discovery), Artem Cherkasov (University of British Columbia), Dennis Pelletier (Pfizer), Chaohong Sun (Abbott), Xavier Barril (University of Barcelona), Jose Duca (Schering-Plough), Terry Stouch (JCAMD), Natasja Brooijmans (Wyeth), Gerard Kleywegt (University of Uppsala), Vladimir Poroikov (Russian Academy of Sciences), Christoph Helma (in silico toxicology), Ann Richard (EPA), Judy Madden (Liverpool John Moores University), Julian Tirado-Rives (Yale), Heather Carlson (University of Michigan), Joseph Tomaszewski (NCI), Joseph Contrera (FDA), Christopher Austin (NIH), Jerome Hert (UCSF), Renate Sekul (Graffinity), Gunther Stahl (Tripos), John W Liebeschuetz (CCDC), Wilfried Langenaeker (Silicos), Zsolt Zsoldos (SimBioSys), Paul Hawkins (OpenEye Scientific Software), François Delfaud (MEDIT), Anatoly Ruvinsky (University of Kansas), Robin Taylor (CCDC), Eric Jamois (Strand Life Sciences), David Gilmour (Tacit), Alex Heiphetz (Delta L Training), Frank Guerino (TraverseIT), Salvatore Alesci (Wyeth), Darius Dziuda (CCSU), Laszlo Boros (Sidmap) Fred Cohen (Fast Track Systems), Alex Tropsha (UNC), Dimitris Agrafiotis, (Johnson & Johnson), Carl Elkin (Schering-Plough)
We will be running poster sessions in the evenings at the meeting with themes: knowledge management (Tuesday), drug design (Wednesday) and drug development and ADMET (Thursday). This option is available to all meeting attendees. Please send your abstract and biography of ca. 300-500 words each to eCheminfo -(at)- douglasconnect.com for approval.
During November I will be planning the 2007 programs for the eCheminfo Advanced Training Week in Oxford and the InterAction Meeting in Bryn Mawr. Please contact me with your interests and proposals!
Latest Advances in Drug Discovery Design & Planning Methods a Hands-on 5 Day eCheminfo Advanced Training Workshop Week June 25-29, Chemical Research Laboratory, Oxford University, Oxford, UK
Latest Advances in Drug Discovery & Development eCheminfo Community of Practice InterAction Meeting 15-18 October 2007, Bryn Mawr College, Philadelphia, PA, USA Themes: Screening, Medicinal Chemistry, Drug Design, Toxicology, Structural Biology, Bioinformatics, Cheminformatics
eCheminfo Gold membership This entitles members to access eCheminfo meeting proceedings including audio, access to our Executive Insights reports from meeting and community of practice activities, and additional member discounts on meeting and training registration fees.
As apparent from our discussions at Bryn Mawr College last week at the eCheminfo and InnovationWell meetings, knowledge management (KM) stands to play a key role in emerging new practices to drug discovery and development, healthcare and new services in personalised medicine. However there is need to improve our understanding of and competency in KM and its emerging best practices to achieve breakthroughs such as innovation success in discovery, product development and improving confidence in safety.
A full five-day Certified Knowledge Manager (CKM) workshop will be held in Basel, 27 November – 1 December 2006. The training will be jointly led for the first time by Swiss faculty who bring their own extensive experience of knowledge management and European practice to enrich the quality of the learning program.
The workshop week will be co-led by Douglas Weidner, President, International Knowledge Management Institute; Pavel Kraus, Founding Partner of aht'intermediation GmbH & President, Swiss Knowledge Management Forum; Beat Knechtli, Director and Chief Knowledge Officer, PwC Switzerland, and Barry Hardy, Director, KM Institute Switzerland
Case Studies & Discussions will be used to illustrate the application of KM principles and best practices.
InnovationWell will hold an Open Seminar & Knowledge Cafe on Electronic Laboratory Notebooks (ELNs) at Bryn Mawr on Tuesday 17 October 2006 to discuss the emerging roles of Knowledge Management and Electronic Laboratory Notebook solutions in managing multidisciplinary research activities, innovation and collaboration. The Open Event will take place alongside the InnovationWell and eCheminfo Autumn InterAction Meetings. Attendance at the Open Event & Knowledge Café involves no registration fee. However seated places are limited and will be restricted to a confirmed guest list of 100. Please send an RSVP with your name and organisation via email to innovationwell [at] douglasconnect.com